These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22714142)

  • 1. Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy.
    Hu YL; Jahangiri A; De Lay M; Aghi MK
    Autophagy; 2012 Jun; 8(6):979-81. PubMed ID: 22714142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.
    Rapisarda A; Melillo G
    Drug Resist Updat; 2009 Jun; 12(3):74-80. PubMed ID: 19394890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy as a mechanism for anti-angiogenic therapy resistance.
    Chandra A; Rick J; Yagnik G; Aghi MK
    Semin Cancer Biol; 2020 Nov; 66():75-88. PubMed ID: 31472232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
    Li C; Liu T; Bazhin AV; Yang Y
    J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors.
    Kes MMG; Van den Bossche J; Griffioen AW; Huijbers EJM
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188427. PubMed ID: 32961257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].
    Cohen-Jonathan Moyal E
    Cancer Radiother; 2009 Oct; 13(6-7):562-7. PubMed ID: 19695923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhaponticin decreases the metastatic and angiogenic abilities of cancer cells via suppression of the HIF‑1α pathway.
    Kim A; Ma JY
    Int J Oncol; 2018 Sep; 53(3):1160-1170. PubMed ID: 30015877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality.
    McIntyre A; Harris AL
    EMBO Mol Med; 2015 Apr; 7(4):368-79. PubMed ID: 25700172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma.
    Hu YL; DeLay M; Jahangiri A; Molinaro AM; Rose SD; Carbonell WS; Aghi MK
    Cancer Res; 2012 Apr; 72(7):1773-83. PubMed ID: 22447568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy, a double-edged sword in anti-angiogenesis therapy.
    Liu J; Fan L; Wang H; Sun G
    Med Oncol; 2016 Jan; 33(1):10. PubMed ID: 26715036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy.
    Hu YL; Jahangiri A; Delay M; Aghi MK
    Cancer Res; 2012 Sep; 72(17):4294-9. PubMed ID: 22915758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
    Erin N; Grahovac J; Brozovic A; Efferth T
    Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-associated autophagy flux dysregulation in human cancers.
    Fu J; Lin J; Dai Z; Lin B; Zhang J
    Cancer Lett; 2024 May; 590():216823. PubMed ID: 38521197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of anti-angiogenic therapy in tumors.
    Zulato E; Curtarello M; Nardo G; Indraccolo S
    Biochimie; 2012 Apr; 94(4):925-31. PubMed ID: 22245704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why do tumors become resistant to antiangiogenesis drugs?
    Schmidt C
    J Natl Cancer Inst; 2009 Nov; 101(22):1530-2. PubMed ID: 19880813
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance.
    Mander KA; Finnie JW
    Aust Vet J; 2018 Oct; 96(10):371-378. PubMed ID: 30255577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.